Nyrada Inc. (ASX:NYR) has made progress on developing NYR-BI03, a first in class neuroprotection treatment for both traumatic brain injury (TBI) and stroke.
– Additional study provided further data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate.
– Rat CNS testing satisfactorily completed under Good Laboratory Practice (GLP) conditions for NYR-BI03.
– Nyrada will continue to report on remaining GLP study results and remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in late CY2024
ASX announcement: https://announcements.asx.com.au/asxpdf/20240806/pdf/066by3mf9gs2jy.pdf